市場調查報告書

先天性水皰症(EB)- 市場洞察,流行病學,預測 2028年

Epidermolysis Bullosa Market Insight, Epidemiology and Market Forecast - 2030

出版商 DelveInsight Business Research LLP 商品編碼 918184
出版日期 內容資訊 英文 150 Pages
商品交期: 最快1-2個工作天內
價格
先天性水皰症(EB)- 市場洞察,流行病學,預測 2028年 Epidermolysis Bullosa Market Insight, Epidemiology and Market Forecast - 2030
出版日期: 2020年01月01日內容資訊: 英文 150 Pages
簡介

主要7個國家(美國、英國、德國、法國、義大利、西班牙、日本)的先天性水皰症(EB)的2017年的患病數估算為3萬9,433人,同年的市場規模估算為22億9,631萬美元。

本報告提供主要7個國家(美國,英國,德國,法國,義大利,西班牙,日本)的先天性水皰症(EB)市場相關調查,疾病概要,新藥的簡介,主要7個國家的市場趨勢,流行病學的預測,市場規模,患病數的變化與預測,未滿足需求,市場成長要素及障礙等資訊總括性彙整。

目錄

第1章 重要洞察

第2章 先天性水皰症(EB)市場概要

  • 先天性水皰症(EB)的分佈(實在數值)
  • 先天性水皰症(EB)的分佈(預測值)

第3章 疾病概要:先天性水皰症(EB)

  • 簡介
  • 原因
  • 症狀
  • 分類
  • 病理生理學
  • 遺傳的基礎
  • 診斷
  • 診斷指南

第4章 流行病學和患者人口

  • 主要調查結果
  • 主要7個國家的先天性水皰症(EB)的總患病數
  • 主要7個國家的先天性水皰症(EB)的診斷患病數
  • 主要7個國家的先天性水皰症(EB)的診斷患病數:各類型

第5章 先天性水皰症(EB)的流行病學預測:各國

  • 美國
    • 先天性水皰症(EB)的總患病數
    • 先天性水皰症(EB)的診斷患病數
    • 先天性水皰症(EB)的診斷患病數:各類型
  • 歐盟5國
    • 德國
      • 先天性水皰症(EB)的總患病數
      • 先天性水皰症(EB)的診斷患病數
      • 先天性水皰症(EB)的診斷患病數:各類型
    • 法國
    • 義大利
    • 西班牙
    • 英國
  • 日本
    • 先天性水皰症(EB)的總患病數
    • 先天性水皰症(EB)的診斷患病數
    • 先天性水皰症(EB)的診斷患病數:各類型

第6章 治療和管理

  • 皮膚、創傷管理
  • 一般的管理原則
  • 考慮事項
  • 先天性水皰症(EB)的慢性創傷的管理
  • 先天性水皰症(EB)疼痛管理:最佳治療的實踐

第7章 未滿足需求

第8章 新藥

  • Key Cross Competition
  • AP-101: Amryt Pharma
    • 產品概要
    • 其他開發趨勢
    • 臨床趨勢
    • 臨床實驗資訊
    • 安全性和有效性
    • 產品簡介
  • EB-101:Abeona Therapeutics
  • CCP-020 (Diacerein 1% Ointment):Castle CreekPharmaceuticals
  • RGN-137:RegeneRx
  • KB103 (Bercolagene Telserpavec):Krystal Biotech
  • FCX-007:Fibrocell Technologies
  • Allo-APZ2-EB:RHEACELL GmbH
  • COL7 and LAMB3 gene therapy: Holostem Terapie Avanzate
  • HMGB1 peptides:Stemrim
  • Failed Therapies for Epidermolysis Bullosa (EB)
  • JR-031:JCR Pharmaceuticals
  • Zorblisa:Amicus Therapeutics

第9章 主要7個國家的先天性水皰症(EB)市場分析

  • 主要調查結果
  • 主要7個國家的整體市場規模
  • 主要7個國家的市場規模:各治療藥物

第10章 美國市場預測

  • 整體市場規模
  • 市場規模:各治療藥物

第11章 歐洲市場預測

  • 德國
    • 整體市場規模
    • 市場規模:各治療藥物
  • 法國
  • 義大利
  • 西班牙
  • 英國

第12章 日本市場預測

  • 整體市場規模
  • 市場規模:各治療藥物

第13章 市場成長要素

第14章 市場障礙

第15章 附錄

第16章 DelveInsight的服務內容

第17章 免責聲明

第18章 關於DelveInsight

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: DIMI0411

DelveInsight's "Epidermolysis Bullosa - Market Insights, Epidemiology, and Market Forecast-2030" report delivers an in-depth understanding of the Epidermolysis Bullosa, historical and forecasted epidemiology as well as the Epidermolysis Bullosa market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The Epidermolysis Bullosa market report provides current treatment practices, emerging drugs, Epidermolysis Bullosa market share of the individual therapies, current and forecasted Epidermolysis Bullosa market Size from 2017 to 2030 segmented by seven major markets. The Report also covers current Epidermolysis Bullosa treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market.

Geography Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2017-2030

Epidermolysis Bullosa Disease Understanding and Treatment Algorithm

The DelveInsight Epidermolysis Bullosa market report gives a thorough understanding of the Epidermolysis Bullosa by including details such as disease definition, symptoms, causes, pathophysiology, diagnosis and treatment.

Diagnosis

This segment of the report covers the detailed diagnostic methods or tests for Epidermolysis Bullosa.

Treatment

It covers the details of conventional and current medical therapies available in the Epidermolysis Bullosa market for the treatment of the condition. It also provides Epidermolysis Bullosa treatment algorithms and guidelines in the United States, Europe, and Japan.

Epidermolysis Bullosa Epidemiology

The Epidermolysis Bullosa epidemiology division provide insights about historical and current Epidermolysis Bullosa patient pool and forecasted trend for every seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

Key Findings

The disease epidemiology covered in the report provides historical as well as forecasted Epidermolysis Bullosa epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2017 to 2030.

Country Wise- Epidermolysis Bullosa Epidemiology

The epidemiology segment also provides the Epidermolysis Bullosa epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

Epidermolysis Bullosa Drug Chapters

Drug chapter segment of the Epidermolysis Bullosa report encloses the detailed analysis of Epidermolysis Bullosa marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the Epidermolysis Bullosa clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.

Marketed Drugs

The report provides the details of the marketed product available for Epidermolysis Bullosa treatment.

Epidermolysis Bullosa Emerging Drugs

The report provides the details of the emerging therapies under the late and mid-stage of development for Epidermolysis Bullosa treatment.

Epidermolysis Bullosa Market Outlook

The Epidermolysis Bullosa market outlook of the report helps to build the detailed comprehension of the historic, current, and forecasted Epidermolysis Bullosa market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.

This segment gives a thorough detail of Epidermolysis Bullosa market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, Epidermolysis Bullosa market in 7MM is expected to change in the study period 2017-2030.

Key Findings

This section includes a glimpse of the Epidermolysis Bullosa market in 7MM.

The United States Market Outlook

This section provides the total Epidermolysis Bullosa market size and market size by therapies in the United States.

EU-5 Countries: Market Outlook

The total Epidermolysis Bullosa market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom is provided in this section.

Japan Market Outlook

The total Epidermolysis Bullosa market size and market size by therapies in Japan is also mentioned.

Epidermolysis Bullosa Drugs Uptake

This section focusses on the rate of uptake of the potential drugs recently launched in the Epidermolysis Bullosa market or expected to get launched in the market during the study period 2017-2030. The analysis covers Epidermolysis Bullosa market uptake by drugs; patient uptake by therapies; and sales of each drug.

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Epidermolysis Bullosa Pipeline Development Activities

The report provides insights into different therapeutic candidates in Phase II, and Phase III stage. It also analyses Epidermolysis Bullosa key players involved in developing targeted therapeutics.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing, patent details and other information for Epidermolysis Bullosa emerging therapies.

Reimbursement Scenario in Epidermolysis Bullosa

Approaching reimbursement proactively can have a positive impact both during the late stages of product development and well after product launch. In a report, we take reimbursement into consideration to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy.

KOL- Views

To keep up with current market trends, we take KOLs and SME's opinion working in Epidermolysis Bullosa domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate current and emerging therapies treatment patterns or Epidermolysis Bullosa market trend. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the market and the unmet needs.

Competitive Intelligence Analysis

We perform Competitive and Market Intelligence analysis of the Epidermolysis Bullosa Market by using various Competitive Intelligence tools that include - SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies etc. The inclusion of the analysis entirely depends upon the data availability.

Scope of the Report

  • The report covers the descriptive overview of Epidermolysis Bullosa, explaining its causes, signs and symptoms, pathophysiology, diagnosis and currently available therapies
  • Comprehensive insight has been provided into the Epidermolysis Bullosa epidemiology and treatment in the 7MM
  • Additionally, an all-inclusive account of both the current and emerging therapies for Epidermolysis Bullosa are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
  • A detailed review of Epidermolysis Bullosa market; historical and forecasted is included in the report, covering drug outreach in the 7MM
  • The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Epidermolysis Bullosa market

Report Highlights

  • In the coming years, Epidermolysis Bullosa market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market
  • The companies and academics are working to assess challenges and seek opportunities that could influence Epidermolysis Bullosa R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition
  • Major players are involved in developing therapies for Epidermolysis Bullosa. Launch of emerging therapies will significantly impact the Epidermolysis Bullosa market
  • A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for Epidermolysis Bullosa
  • Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities

Epidermolysis Bullosa Report Insights

  • Patient Population
  • Therapeutic Approaches
  • Epidermolysis Bullosa Pipeline Analysis
  • Epidermolysis Bullosa Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies

Epidermolysis Bullosa Report Key Strengths

  • 11 Years Forecast
  • 7MM Coverage

Epidermolysis Bullosa Epidemiology Segmentation

  • Key Cross Competition
  • Highly Analyzed Market
  • Drugs Uptake

Epidermolysis Bullosa Report Assessment

  • Current Treatment Practices
  • Unmet Needs
  • Pipeline Product Profiles
  • Market Attractiveness
  • Market Drivers and Barriers

Key Questions

Market Insights:

  • What was the Epidermolysis Bullosa market share (%) distribution in 2017 and how it would look like in 2030?
  • What would be the Epidermolysis Bullosa total market size as well as market size by therapies across the 7MM during the forecast period (2017-2030)?
  • What are the key findings pertaining to the market across 7MM and which country will have the largest Epidermolysis Bullosa market size during the forecast period (2017-2030)?
  • At what CAGR, the Epidermolysis Bullosa market is expected to grow in 7MM during the forecast period (2017-2030)?
  • What would be the Epidermolysis Bullosa market outlook across the 7MM during the forecast period (2017-2030)?
  • What would be the Epidermolysis Bullosa market growth till 2030, and what will be the resultant market Size in the year 2030?
  • How would the market drivers, barriers and future opportunities affect the market dynamics and subsequent analysis of the associated trends?

Epidemiology Insights:

  • What is the disease risk, burden and unmet needs of the Epidermolysis Bullosa?
  • What is the historical Epidermolysis Bullosa patient pool in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
  • What would be the forecasted patient pool of Epidermolysis Bullosa in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
  • What will be the growth opportunities in the 7MM with respect to the patient population pertaining to Epidermolysis Bullosa?
  • Out of all 7MM countries, which country would have the highest prevalent population of Epidermolysis Bullosa during the forecast period (2017-2030)?
  • At what CAGR the population is expected to grow in 7MM during the forecast period (2017-2030)?
  • Current Treatment Scenario, Marketed Drugs and Emerging Therapies:
  • What are the current options for the Epidermolysis Bullosa treatment, along with the approved therapy?
  • What are the current treatment guidelines for the treatment of Epidermolysis Bullosa in the USA, Europe, and Japan?
  • What are the Epidermolysis Bullosa marketed drugs and their MOA, regulatory milestones, product development activities, advantages, disadvantages, safety and efficacy, etc.?
  • How many companies are developing therapies for the treatment of Epidermolysis Bullosa?
  • How many therapies are developed by each company for Epidermolysis Bullosa treatment?
  • How many are emerging therapies in mid-stage, and late stage of development for Epidermolysis Bullosa treatment?
  • What are the key collaborations (Industry - Industry, Industry - Academia), Mergers and acquisitions, licensing activities related to the Epidermolysis Bullosa therapies?
  • What are the recent novel therapies, targets, mechanisms of action and technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Epidermolysis Bullosa and their status?
  • What are the key designations that have been granted for the emerging therapies for Epidermolysis Bullosa?
  • What are the global historical and forecasted market of Epidermolysis Bullosa?

Reasons to buy

  • The report will help in developing business strategies by understanding trends shaping and driving the Epidermolysis Bullosa market
  • To understand the future market competition in the Epidermolysis Bullosa market and Insightful review of the key market drivers and barriers
  • Organize sales and marketing efforts by identifying the best opportunities for Epidermolysis Bullosa in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom) and Japan
  • Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors
  • Organize sales and marketing efforts by identifying the best opportunities for Epidermolysis Bullosa market
  • To understand the future market competition in the Epidermolysis Bullosa market

Table of Contents

1. Key Insights

2. Executive Summary of Epidermolysis Bullosa

3. Competitive Intelligence Analysis for Epidermolysis Bullosa

4. Epidermolysis Bullosa: Market Overview at a Glance

  • 4.1. Epidermolysis Bullosa Total Market Share (%) Distribution in 2017
  • 4.2. Epidermolysis Bullosa Total Market Share (%) Distribution in 2030

5. Epidermolysis Bullosa: Disease Background and Overview

  • 5.1. Introduction
  • 5.2. Sign and Symptoms
  • 5.3. Pathophysiology
  • 5.4. Risk Factors
  • 5.5. Diagnosis

6. Patient Journey

7. Epidermolysis Bullosa Epidemiology and Patient Population

  • 7.1. Epidemiology Key Findings
  • 7.2. Assumptions and Rationale: 7MM
  • 7.3. Epidemiology Scenario: 7MM
    • 7.3.1. Epidermolysis Bullosa Epidemiology Scenario in the 7MM (2017-2030)
  • 7.4. United States Epidemiology
    • 7.4.1. Epidermolysis Bullosa Epidemiology Scenario in the United States (2017-2030)
  • 7.5. EU-5 Country-wise Epidemiology
    • 7.5.1. Germany Epidemiology
      • 7.5.1.1. Epidermolysis Bullosa Epidemiology Scenario in Germany (2017-2030)
    • 7.5.2. France Epidemiology
      • 7.5.2.1. Epidermolysis Bullosa Epidemiology Scenario in France (2017-2030)
    • 7.5.3. Italy Epidemiology
      • 7.5.3.1. Epidermolysis Bullosa Epidemiology Scenario in Italy (2017-2030)
    • 7.5.4. Spain Epidemiology
      • 7.5.4.1. Epidermolysis Bullosa Epidemiology Scenario in Spain (2017-2030)
    • 7.5.5. United Kingdom Epidemiology
      • 7.5.5.1. Epidermolysis Bullosa Epidemiology Scenario in the United Kingdom (2017-2030)
    • 7.5.6. Japan Epidemiology
      • 7.5.6.1. Epidermolysis Bullosa Epidemiology Scenario in Japan (2017-2030)

8. Treatment Algorithm, Current Treatment, and Medical Practices

  • 8.1. Epidermolysis Bullosa Treatment and Management
  • 8.2. Epidermolysis Bullosa Treatment Algorithm

9. Unmet Needs

10. Key Endpoints of Epidermolysis Bullosa Treatment

11. Marketed Products

  • 11.1. List of Marketed Products in the 7MM
  • 11.2. Drug Name: Company Name
    • 11.2.1. Product Description
    • 11.2.2. Regulatory Milestones
    • 11.2.3. Other Developmental Activities
    • 11.2.4. Pivotal Clinical Trials
    • 11.2.5. Summary of Pivotal Clinical Trial

List to be continued in report

12. Emerging Therapies

  • 12.1. Key Cross
  • 12.2. Drug Name: Company Name
    • 12.2.1. Product Description
    • 12.2.2. Other Developmental Activities
    • 12.2.3. Clinical Development
    • 12.2.4. Safety and Efficacy
    • 12.2.5. Product Profile

List to be continued in report

13. Epidermolysis Bullosa: Seven Major Market Analysis

  • 13.1. Key Findings
  • 13.2. Epidermolysis Bullosa Market Size in 7MM
  • 13.3. Epidermolysis Bullosa Market Size by Therapies in the 7MM

14. Attribute analysis

15. 7MM: Market Outlook

  • 15.1. United States: Market Size
    • 15.1.1. Epidermolysis Bullosa Total Market Size in the United States
    • 15.1.2. Epidermolysis Bullosa Market Size by Therapies in the United States
  • 15.2. EU-5 countries: Market Size and Outlook
  • 15.3. Germany Market Size
    • 15.3.1. Epidermolysis Bullosa Total Market Size in Germany
    • 15.3.2. Epidermolysis Bullosa Market Size by Therapies in Germany
  • 15.4. France Market Size
    • 15.4.1. Epidermolysis Bullosa Total Market Size in France
    • 15.4.2. Epidermolysis Bullosa Market Size by Therapies in France
  • 15.5. Italy Market Size
    • 15.5.1. Epidermolysis Bullosa Total Market Size in Italy
    • 15.5.2. Epidermolysis Bullosa Market Size by Therapies in Italy
  • 15.6. Spain Market Size
    • 15.6.1. Epidermolysis Bullosa Total Market Size in Spain
    • 15.6.2. Epidermolysis Bullosa Market Size by Therapies in Spain
  • 15.7. United Kingdom Market Size
    • 15.7.1. Epidermolysis Bullosa Total Market Size in the United Kingdom
    • 15.7.2. Epidermolysis Bullosa Market Size by Therapies in the United Kingdom
  • 15.8. Japan Market Outlook
    • 15.8.1. Japan Market Size
    • 15.8.2. Epidermolysis Bullosa Total Market Size in Japan
    • 15.8.3. Epidermolysis Bullosa Market Size by Therapies in Japan

16. Access and Reimbursement Overview of Epidermolysis Bullosa

17. KOL Views

18. Market Drivers

19. Market Barriers

20. Appendix

  • 20.1. Bibliography
  • 20.2. Report Methodology

21. DelveInsight Capabilities

22. Disclaimer

23. About DelveInsight

List of Tables

  • Table 1 : 7MM Epidermolysis Bullosa Epidemiology (2017-2030)
  • Table 2 : 7MM Epidermolysis Bullosa Diagnosed and Treatable Cases (2017-2030)
  • Table 3 : Disease% Epidemiology in the United States (2017-2030)
  • Table 4 : Epidermolysis Bullosa Diagnosed and Treatable Cases in the United States (2017-2030)
  • Table 5 : Epidermolysis Bullosa Epidemiology in Germany (2017-2030)
  • Table 6 : Epidermolysis Bullosa Diagnosed and Treatable Cases in Germany (2017-2030)
  • Table 7 : Epidermolysis Bullosa Epidemiology in France (2017-2030)
  • Table 8 : Epidermolysis Bullosa Diagnosed and Treatable Cases in France (2017-2030)
  • Table 9 : Epidermolysis Bullosa Epidemiology in Italy (2017-2030)
  • Table 10 : Epidermolysis Bullosa Diagnosed and Treatable Cases in Italy (2017-2030)
  • Table 11 : Epidermolysis Bullosa Epidemiology in Spain (2017-2030)
  • Table 12 : Epidermolysis Bullosa Diagnosed and Treatable Cases in Spain (2017-2030)
  • Table 13 : Epidermolysis Bullosa Epidemiology in the UK (2017-2030)
  • Table 14 : Epidermolysis Bullosa Diagnosed and Treatable Cases in the UK (2017-2030)
  • Table 15 : Epidermolysis Bullosa Epidemiology in Japan (2017-2030)
  • Table 16 : Epidermolysis Bullosa Diagnosed and Treatable Cases in Japan (2017-2030)
  • Table 17 : Drug Name, Clinical Trials by Recruitment status
  • Table 18 : Drug Name, Clinical Trials by Zone
  • Table 19 : Total Seven Major Market Size in USD, Million (2017-2030)
  • Table 20 : Region-wise Market Size in USD, Million (2017-2030)
  • Table 21 : 7MM-Market Size by Therapy in USD, Million (2017-2030)
  • Table 22 : United States Market Size in USD, Million (2017-2030)
  • Table 23 : United States Market Size by Therapy in USD, Million (2017-2030)
  • Table 24 : Germany Market Size in USD, Million (2017-2030)
  • Table 25 : Germany Market Size by Therapy in USD, Million (2017-2030)
  • Table 26 : France Market Size in USD, Million (2017-2030)
  • Table 27 : France Market Size by Therapy in USD, Million (2017-2030)
  • Table 28 : Italy Market Size in USD, Million (2017-2030)
  • Table 29 : Italy Market Size by Therapy in USD, Million (2017-2030)
  • Table 30 : Spain Market Size in USD, Million (2017-2030)
  • Table 31 : Spain Market Size by Therapy in USD, Million (2017-2030)
  • Table 32 : United Kingdom Market Size in USD, Million (2017-2030)
  • Table 33 : United Kingdom Market Size by Therapy in USD, Million (2017-2030)
  • Table 34 : Japan Market Size in USD, Million (2017-2030)
  • Table 35 : Japan Market Size by Therapy in USD, Million (2017-2030)

List of Figures

  • Figure 1 : 7MM Epidermolysis Bullosa Epidemiology (2017-2030)
  • Figure 2 : 7MM Epidermolysis Bullosa Diagnosed and Treatable Cases (2017-2030)
  • Figure 3 : Epidermolysis Bullosa Epidemiology in the United States (2017-2030)
  • Figure 4 : Epidermolysis Bullosa Diagnosed and Treatable Cases in the United States (2017-2030)
  • Figure 5 : Epidermolysis Bullosa Epidemiology in Germany (2017-2030)
  • Figure 6 : Epidermolysis Bullosa Diagnosed and Treatable Cases in Germany (2017-2030)
  • Figure 7 : Epidermolysis Bullosa Epidemiology in France (2017-2030)
  • Figure 8 : Epidermolysis Bullosa Diagnosed and Treatable Cases in France (2017-2030)
  • Figure 9 : Epidermolysis Bullosa Epidemiology in Italy (2017-2030)
  • Figure 10 : Epidermolysis Bullosa Diagnosed and Treatable Cases in Italy (2017-2030)
  • Figure 11 : Epidermolysis Bullosa Epidemiology in Spain (2017-2030)
  • Figure 12 : Epidermolysis Bullosa Diagnosed and Treatable Cases in Spain (2017-2030)
  • Figure 13 : Epidermolysis Bullosa Epidemiology in the UK (2017-2030)
  • Figure 14 : Epidermolysis Bullosa Diagnosed and Treatable Cases in the UK (2017-2030)
  • Figure 15 : Epidermolysis Bullosa Epidemiology in Japan (2017-2030)
  • Figure 16 : Epidermolysis Bullosa Diagnosed and Treatable Cases in Japan (2017-2030)
  • Figure 17 : Drug Name, Clinical Trials by Recruitment status
  • Figure 18 : Drug Name, Clinical Trials by Zone
  • Figure 19 : Total Seven Major Market Size in USD, Million (2017-2030)
  • Figure 20 : Region-wise Market Size in USD, Million (2017-2030)
  • Figure 21 : 7MM-Market Size by Therapy in USD, Million (2017-2030)
  • Figure 22 : United States Market Size in USD, Million (2017-2030)
  • Figure 23 : United States Market Size by Therapy in USD, Million (2017-2030)
  • Figure 24 : Germany Market Size in USD, Million (2017-2030)
  • Figure 25 : Germany Market Size by Therapy in USD, Million (2017-2030)
  • Figure 26 : France Market Size in USD, Million (2017-2030)
  • Figure 27 : France Market Size by Therapy in USD, Million (2017-2030)
  • Figure 28 : Italy Market Size in USD, Million (2017-2030)
  • Figure 29 : Italy Market Size by Therapy in USD, Million (2017-2030)
  • Figure 30 : Spain Market Size in USD, Million (2017-2030)
  • Figure 31 : Spain Market Size by Therapy in USD, Million (2017-2030)
  • Figure 32 : United Kingdom Market Size in USD, Million (2017-2030)
  • Figure 33 : United Kingdom Market Size by Therapy in USD, Million (2017-2030)
  • Figure 34 : Japan Market Size in USD, Million (2017-2030)
  • Figure 35 : Japan Market Size by Therapy in USD, Million (2017-2030)